On July 7, 2022 Emergent BioSolutions Inc. (NYSE: EBS) reported that it has entered into an agreement with Ridgeback Biotherapeutics ("Ridgeback Bio"), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga (Ansuvimab-zykl) (Press release, Emergent BioSolutions, JUL 7, 2022, View Source [SID1234616551]). Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga, ensuring it remains available to patients in endemic countries free of charge through Ridgeback Bio’s compassionate use program. Ebanga was approved by the U.S. Food and Drug Administration (FDA) in December 2020 for the treatment of Ebola.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ebanga is a monoclonal antibody with antiviral activity provided through a single injection and was developed for the treatment of Ebola by Ridgeback Bio under license from the National Institute of Allergy and Infectious Diseases. Ridgeback Bio provided funding and operational support for clinical testing, with additional funding received under contracts with the Biomedical Advanced Research and Development Authority for late-stage manufacturing and regulatory activities and ensured that the work necessary for FDA approval of Ebanga was completed.
"This relationship with Ridgeback Bio builds on our strategic focus and deep expertise in developing and supplying medical countermeasures against serious health threats," said Robert G. Kramer, CEO of Emergent. "Ebanga is crucial in the ongoing fight to contain Ebola and we are excited about the future of this collaboration to create a healthier, more secure world."
"We’re thrilled to collaborate with Emergent BioSolutions in making sure that the United States and Canada receive the supply they need of Ebanga, while also continuing our ongoing local support for the prompt treatment of outbreaks that includes free patient access and funding on-the-ground support through our Rapid Response Program," said Wendy Holman, CEO of Ridgeback Bio.
About Ebanga
Ebanga (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single injection. Ebanga development has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Numbers 75A50119C00059 and 75A50120C00009.